Glenmark Pharmaceuticals Ltd said its Swiss arm has entered into an exclusive licensing agreement with Lotus International Pte Ltd for commercialising its innovative nasal spray Ryaltris in Singapore, Hong Kong and Vietnam.
- SpaceX Launches 21 Starlink Satellites from Florida
- Govt Begins Tur Procurement, Commits to 100% Purchase of Tur, Urad & Masur
- Russia, US May Start Ukraine Peace Talks Today
- Govt Begins India’s First Exploration Licence Auction for Critical Minerals
- BEML Shares Soar 6% on Inking MoUs with Siemens and Dragflow SRL
Under the agreement signed between Glenmark Specialty SA and the wholly-owned subsidiary of Lotus Pharmaceutical Co, Ltd (Lotus), Glenmark will be responsible for the manufacturing and supply of Ryaltris.
On the other hand Lotus will be responsible for its commercialization subject to receipt of regulatory approvals, in these markets, the company said in a statement.
